Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index

10. april 2015 oppdatert av: Amy Paller, Northwestern University

Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index and Comorbid Risk Factors: an Epidemiologic Analysis

The object of this research study is to examine these associations in children as very little is known about psoriasis and cardiovascular risk factors in the pediatric population.

Studieoversikt

Detaljert beskrivelse

Several environmental factors and comorbid conditions have been found to be associated with psoriasis in adults, including obesity, depression, smoking, and other cardiovascular risk factors such as high blood pressure. The object of this research study is to examine these associations in children as very little is known about psoriasis and cardiovascular risk factors in the pediatric population.

This is a multi-center study with a planned total enrollment of about 200 subjects ages 2-17 years old with psoriasis and 100 aged-match controls. Patient and family history will be recorded. All subjects will undergo standard height, weight, blood pressure, and waist circumference (WC). For the obese and overweight subjects we will also obtain their growth charts to attempt to correlate weight gain with psoriasis onset and progression. All data will be compiled and then statistically analyzed.

Studietype

Observasjonsmessig

Registrering (Faktiske)

409

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Canada
        • Nexus Clinical Resarch
      • Santiago, Chile
        • Pontificia universidad catolica de Chile
    • California
      • San Diego, California, Forente stater, 92123
        • University of California, San Diego
      • San Francisco, California, Forente stater, 94143
        • University of California, San Francisco
      • Stanford, California, Forente stater, 94305
        • Stanford University School of Medicine
    • Illinois
      • Chicago, Illinois, Forente stater, 60611
        • Ann & Robert H Lurie Children's Hospital of Chicago
    • Massachusetts
      • Worcester, Massachusetts, Forente stater, 01605
        • UMass Memorial Dermatology Center
    • Missouri
      • St. Louis, Missouri, Forente stater, 63117-1206
        • Central Dermatology
    • Ohio
      • Cleveland, Ohio, Forente stater, 44106
        • University Hospitals, Case Medical Centers
    • Texas
      • Dallas, Texas, Forente stater, 75246
        • Texas Dermatology Associates
      • Houston, Texas, Forente stater, 77030
        • Texas Children's Hospital
      • Tuen Mun, Hong Kong
        • University of Hong Kong
      • Verona, Italia
        • Universita Verona
      • Nijmegen, Nederland
        • UMC St. Radboud

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

5 år til 17 år (Barn)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Sannsynlighetsprøve

Studiepopulasjon

  1. Children ages 5 to 17 years old with either moderate or severe plaque type psoriasis
  2. Children ages 5 to 17 years old with moderate or severe atopic dermatitis
  3. Children ages 5 to 17 years old seen in dermatology clinic who are healthy and without a systemic disorder.

Beskrivelse

Inclusion Criteria:

  • Subjects must be between the ages of 5 and 17 years at the time of enrollment.
  • Subjects of either sex.
  • Subjects who have had psoriatic plaques for more than 6 months.
  • Subjects and guardians of minors must sign the approved IRB consent form(s) prior to initiation of the study protocol.
  • Subjects enrolled as "non-inflammatory" normal controls will carry a common non- systemic skin condition, such as acne, nevi, warts and molluscum as their main diagnosis.
  • Subjects enrolled as "inflammatory" normal controls will carry a diagnosis of moderate to severe atopic dermatitis.

Exclusion Criteria:

  • Subjects who are unable to give informed consent or assent.
  • Subjects who have had psoriasis for less than 6 months.
  • Subjects whose condition is deemed unsafe or incapable by the study investigator for study participation.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Psoriasis
Children ages 5-17 years old with moderate or severe plaque type psoriasis. Blood pressure will be measured once while patient is seated Height will be measured in centimeters at the time of enrollment Weight will be measured in kilograms at enrollment Body Mass Index (BMI) will be calculated from a subject's height and weight Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
Blood pressure will be measured once while patient is seated
Height will be measured in centimeters at the time of enrollment
Weight will be measured in kilograms at enrollment
Body Mass Index (BMI) will be calculated from a subject's height and weight
Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
Atopic Dermatitis Controls
Children ages 5 to 17 years old with moderate to severe atopic dermatitis. Blood pressure will be measured once while patient is seated Height will be measured in centimeters at the time of enrollment Weight will be measured in kilograms at enrollment Body Mass Index (BMI) will be calculated from a subject's height and weight Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
Blood pressure will be measured once while patient is seated
Height will be measured in centimeters at the time of enrollment
Weight will be measured in kilograms at enrollment
Body Mass Index (BMI) will be calculated from a subject's height and weight
Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
Healthy Controls

Children 5-17 years of age who are healthy and seen in dermatology clinic for a non-systemic skin condition.

Blood pressure will be measured once while patient is seated Height will be measured in centimeters at the time of enrollment Weight will be measured in kilograms at enrollment Body Mass Index (BMI) will be calculated from a subject's height and weight Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm

Blood pressure will be measured once while patient is seated
Height will be measured in centimeters at the time of enrollment
Weight will be measured in kilograms at enrollment
Body Mass Index (BMI) will be calculated from a subject's height and weight
Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
BMI
Tidsramme: 07/2010
07/2010

Sekundære resultatmål

Resultatmål
Tidsramme
Blood Pressure
Tidsramme: 07/2010
07/2010
Waist circumference
Tidsramme: 07/2010
07/2010

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. mai 2009

Primær fullføring (Faktiske)

1. juni 2012

Studiet fullført (Faktiske)

1. juli 2012

Datoer for studieregistrering

Først innsendt

10. april 2009

Først innsendt som oppfylte QC-kriteriene

10. april 2009

Først lagt ut (Anslag)

13. april 2009

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

14. april 2015

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. april 2015

Sist bekreftet

1. april 2015

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Psoriasis

Kliniske studier på Blood pressure

3
Abonnere